莫西沙星在慢性阻塞性肺疾病中的应用：住院患者和重症监护病房患者的药代动力学和支气管分泌物穿透率。
Moxifloxacin in Chronic Obstructive Pulmonary Disease: Pharmacokinetics and Penetration into Bronchial Secretions in Ward and Intensive Care Unit Patients.
机构信息
Pulmonary Department, Aristotle University of Thessaloniki, G. H. "G. Papanikolaou" (Exohi), Thessaloniki, Greece
Respiratory Intensive Care Unit, Aristotle University of Thessaloniki, G. H. "G. Papanikolaou" (Exohi), Thessaloniki, Greece.
出版信息
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.01974-18. Print 2019 Mar.
Abstract
This study aimed to evaluate the pharmacokinetic profile of moxifloxacin (MXF) in serum and sputum/bronchial secretions of 22 patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) hospitalized in the ward and intensive care unit (ICU). The data showed that ICU patients had lower concentrations in secretions ( = 0.01). However, no other statistically significant differences were observed in pharmacokinetic parameters and penetration in secretions between ward and ICU patients. MXF showed a favorable pharmacokinetic profile, and the pharmacodynamic targets for common pathogens for AECOPD were achieved.
摘要
本研究旨在评估 22 例慢性阻塞性肺疾病急性加重（AECOPD）住院患者（普通病房和重症监护病房）的血清和痰液/支气管分泌物中莫西沙星（MXF）的药代动力学特征。数据显示，重症监护病房患者的分泌物中浓度较低（=0.01）。然而，普通病房和重症监护病房患者的药代动力学参数和分泌物中的渗透情况没有观察到其他统计学上的显著差异。莫西沙星表现出良好的药代动力学特征，达到了 AECOPD 常见病原体的药效学目标。
相似文献
1
Moxifloxacin in Chronic Obstructive Pulmonary Disease: Pharmacokinetics and Penetration into Bronchial Secretions in Ward and Intensive Care Unit Patients.莫西沙星在慢性阻塞性肺疾病中的应用：住院患者和重症监护病房患者的药代动力学和支气管分泌物穿透率。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.01974-18. Print 2019 Mar.
2
Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease.环丙沙星的药代动力学及其在慢性阻塞性肺疾病机械通气患者支气管分泌物中的渗透。
Antimicrob Agents Chemother. 2011 Sep;55(9):4149-53. doi: 10.1128/AAC.00566-10. Epub 2011 Jun 13.
3
Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice.莫西沙星是否是胰腺感染的治疗选择？血清和胰液的药物代谢动力学分析。
J Clin Pharmacol. 2019 Oct;59(10):1405-1414. doi: 10.1002/jcph.1445. Epub 2019 May 20.
4
Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: Prevalence, risk factors, and outcome.慢性阻塞性肺疾病严重急性加重患者中的多重耐药菌：患病率、危险因素及转归
Crit Care Med. 2006 Dec;34(12):2959-66. doi: 10.1097/01.CCM.0000245666.28867.C6.
5
Procalcitonin levels in acute exacerbation of COPD admitted in ICU: a prospective cohort study.重症监护病房收治的慢性阻塞性肺疾病急性加重患者的降钙素原水平：一项前瞻性队列研究。
BMC Infect Dis. 2008 Oct 23;8:145. doi: 10.1186/1471-2334-8-145.
6
Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia.莫西沙星在重症支气管肺炎患者血浆和支气管分泌物中的群体药代动力学。
Clin Pharmacol Ther. 2003 Oct;74(4):353-63. doi: 10.1016/S0009-9236(03)00201-7.
7
Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next exacerbation than moxifloxacin for outpatients with acute exacerbations of chronic obstructive pulmonary disease.奈诺沙星在改善慢性阻塞性肺疾病急性加重患者的症状和延长下次加重时间方面优于莫西沙星。
Sci Rep. 2023 Oct 7;13(1):16954. doi: 10.1038/s41598-023-44188-2.
8
Acute exacerbations of chronic obstructive pulmonary disease: diagnosis, management, and prevention in critically ill patients.慢性阻塞性肺疾病急性加重：危重症患者的诊断、管理与预防
Pharmacotherapy. 2015 Jun;35(6):631-48. doi: 10.1002/phar.1599. Epub 2015 Jun 1.
9
Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease.慢性阻塞性肺疾病急性加重的微生物学决定因素
Arch Intern Med. 2005 Apr 25;165(8):891-7. doi: 10.1001/archinte.165.8.891.
10
C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease.C 反应蛋白水平可预测慢性阻塞性肺疾病患者的细菌恶化。
Am J Med Sci. 2013 Mar;345(3):190-4. doi: 10.1097/MAJ.0b013e318253c921.
引用本文的文献
1
Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review-Part II.重症监护病房患者抗菌药物的组织穿透性：系统评价 - 第二部分
Antibiotics (Basel). 2022 Sep 3;11(9):1193. doi: 10.3390/antibiotics11091193.
2
Key Factors in Effective Patient-Tailored Dosing of Fluoroquinolones in Urological Infections: Interindividual Pharmacokinetic and Pharmacodynamic Variability.泌尿系统感染中氟喹诺酮类药物有效个体化给药的关键因素：个体间药代动力学和药效学变异性
Antibiotics (Basel). 2022 May 11;11(5):641. doi: 10.3390/antibiotics11050641.
本文引用的文献
1
A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia.肠内莫西沙星治疗血液透析患者肺炎的疗效、安全性及药代动力学的前瞻性研究
Intern Med. 2017;56(11):1315-1319. doi: 10.2169/internalmedicine.56.8369. Epub 2017 Jun 1.
2
The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.感染模型和 PK/PD 模型在优化重症感染危重症患者治疗中的作用。
Intensive Care Med. 2017 Jul;43(7):1021-1032. doi: 10.1007/s00134-017-4780-6. Epub 2017 Apr 13.
3
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.慢性阻塞性肺疾病全球策略：诊断、管理与预防 2017 年报告。GOLD 执行摘要。
Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582. doi: 10.1164/rccm.201701-0218PP.
4
Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.莫西沙星在社区获得性肺炎经验性治疗中的药代动力学特征及疗效评估
Antimicrob Agents Chemother. 2015 Apr;59(4):2398-404. doi: 10.1128/AAC.04659-14. Epub 2015 Feb 9.
5
How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?我们如何利用治疗药物监测来改善重症患者严重感染的治疗效果？
BMC Infect Dis. 2014 Nov 28;14:288. doi: 10.1186/1471-2334-14-288.
6
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.个体化抗生素剂量给药用于危重症患者：挑战与潜在解决方案。
Lancet Infect Dis. 2014 Jun;14(6):498-509. doi: 10.1016/S1473-3099(14)70036-2. Epub 2014 Apr 24.
7
Moxifloxacin in lower respiratory tract infections: in silico simulation of different bacterial resistance and drug exposure scenarios.
J Chemother. 2014 Apr;26(2):80-5. doi: 10.1179/1973947813Y.0000000106. Epub 2013 Dec 6.
8
Clinical implications of antibiotic pharmacokinetic principles in the critically ill.抗生素药代动力学原理在危重病患者中的临床意义。
Intensive Care Med. 2013 Dec;39(12):2070-82. doi: 10.1007/s00134-013-3088-4. Epub 2013 Sep 18.
9
Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections.莫西沙星和高剂量左氧氟沙星在重症下呼吸道感染中的药代动力学。
Int J Antimicrob Agents. 2013 Sep;42(3):262-7. doi: 10.1016/j.ijantimicag.2013.04.028. Epub 2013 Jul 4.
10
Guidelines for the management of adult lower respiratory tract infections--full version.成人下呼吸道感染管理指南——全文版。
Clin Microbiol Infect. 2011 Nov;17 Suppl 6(Suppl 6):E1-59. doi: 10.1111/j.1469-0691.2011.03672.x.
Zotero 插件